Another current phase I clinical trial (NCT00436254) is investigating the side effects and best dose of vaccine therapy in combination with sargramostim, an immunostimulatory based on granulocyte macrophage colony-stimulating factor, in stage III-IV HER-2 positive breast cancer and OC [137]. The gene discussed is ERBB2; the disease is breast cancer.